Login
E-mail
Password
Mostra password
Ricorda
Password dimenticata?
Iscriviti gratuitamente
Registrazione
Registrazione
Parametri
Parametri
Quotazioni dinamiche 
OFFON

MATINAS BIOPHARMA HOLDINGS, INC.

(MTNB)
RiassuntoQuotazioniGraficiNotizieRatingAgendaSocietàFinanzaConsensusRevisioniDerivati 
RiassuntoTutte le notizieRaccomandazione analistiAltre lingueComunicati stampaPubblicazioni ufficialiNotizie del settore
Notizie in altre lingue su MATINAS BIOPHARMA HOLDINGS, INC.
18/11Matinas BioPharma to Participate in 33rd Annual Piper Sandler Virtual Healthcare Confer..
08/11Matinas BioPharma Reports Third Quarter 2021 Financial Results and Operational Highligh..
08/11Note 2 - Liquidity and Plan of Operations
08/11Matinas BioPharma Holdings, Inc. Reports Earnings Results for the Third Quarter and Nin..
08/11Matinas BioPharma Reports Third Quarter 2021 Financial Results and Operational Highligh..
02/11Matinas BioPharma to Webcast Conference Call Discussing Third Quarter 2021 Financial an..
01/11MATINAS BIOPHARMA HOLDINGS, INC.: Submission of Matters to a Vote of Security Holders (fo..
01/11Matinas BioPharma Holdings, Inc. Elects Kathryn Corzo to the Board of Directors
25/10MATINAS BIOPHARMA: Selected to Participate in the B. Riley Fall 2021 Growth Biotech Best ..
21/10MATINAS BIOPHARMA: Doses First Patient in Phase 1 Study of Antibiotic Drug Candidate
21/10Matinas BioPharma Initiates Dosing in Phase 1 Study of Potential First Oral Aminoglycos..
21/10MATINAS BIOPHARMA: Initiates Dosing in Phase 1 Study of Potential First Oral Aminoglycosi..
21/10Matinas BioPharma Initiates Dosing in Phase 1 Study of Potential First Oral Aminoglycos..
20/09MATINAS BIOPHARMA: Announces Accomplished Biotechnology Executive and Drug Developer Kath..
20/09MATINAS BIOPHARMA HOLDINGS, INC.: Change in Directors or Principal Officers, Regulation F..
20/09MATINAS BIOPHARMA: Announces Accomplished Biotechnology Executive and Drug Developer Kath..
17/09Matinas Biopharma Holdings, Inc. Announces Resignation of Patrick Le Pore as Director
14/09Matinas BioPharma Announces Webcast of Presentation at the H.C. Wainwright Global Inves..
13/09MATINAS BIOPHARMA: Says MAT2203 Exceeds Primary Endpoint Threshold of Fungal Clearance in..
13/09MATINAS BIOPHARMA: Announces Positive Data in the Ongoing EnACT Trial of MAT2203 (Oral Am..
13/09MATINAS BIOPHARMA HOLDINGS, INC.: Regulation FD Disclosure, Other Events, Financial State..
13/09Matinas BioPharma Announces Positive Data in the Ongoing EnACT Trial of MAT2203 (Oral A..
13/09Matinas Biopharma Announces Positive Data in the Ongoing Enact Trial of Mat2203 for the..
16/08MATINAS BIOPHARMA: Secures US Patent on MAT2203 to Treat or Prevent Cryptococcus Infectio..
16/08MATINAS BIOPHARMA: Announces Issuance of U.S. Patent Protecting MAT2203 to Treat or Preve..
10/08MATINAS BIOPHARMA: Positive recent FDA feedback on MAT2501 (oral amikacin) development pr..
10/08MATINAS BIOPHARMA: Note 2 - Liquidity and Plan of Operations
10/08MATINAS BIOPHARMA: Reports Second Quarter 2021 Financial Results and Operational Highligh..
10/08Matinas Biopharma Holdings, Inc. Reports Earnings Results for the Second Quarter Ended ..
03/08Matinas BioPharma to Participate in BTIG Virtual Biotechnology Conference
27/07MATINAS BIOPHARMA: to Webcast Conference Call Discussing Second Quarter 2021 Financial an..
20/05Matinas BioPharma to Hold Virtual R&D Day on June 17, 2021
12/05MATINAS BIOPHARMA: MAT2501 (oral amikacin) advanced into preclinical toxicology and effic..
10/05MATINAS BIOPHARMA: Note 2 - Liquidity and Plan of Operations
10/05Matinas Biopharma Holdings, Inc. Reports Earnings Results for the First Quarter Ended M..
10/05Matinas BioPharma Reports First Quarter 2021 Financial Results and Operational Highligh..
28/04Matinas BioPharma to Participate in 7th Annual Truist Securities Life Sciences Summit
27/04MATINAS BIOPHARMA: to Webcast Conference Call Discussing First Quarter 2021 Financial and..
27/04Matinas BioPharma to Webcast Conference Call Discussing First Quarter 2021 Financial an..
16/04MATINAS BIOPHARMA: Investor Presentation
08/04Matinas BioPharma to Present at the Needham Healthcare Conference
29/03Matinas Biopharma Holdings, Inc. Reports Earnings Results for the Fourth Quarter Ended ..
29/03MATINAS BIOPHARMA: Management's Discussion And Analysis Of Financial Condition And Result..
29/03Matinas BioPharma Reports Fourth Quarter and Full Year 2020 Financial Results and Opera..
15/03MATINAS BIOPHARMA: to Webcast Conference Call Discussing Fourth Quarter and Full Year 202..
01/03Matinas BioPharma to Present at the Barclays Global Healthcare Conference
01/02MATINAS BIOPHARMA HOLDINGS, INC.: Regulation FD Disclosure, Other Events, Financial State..
01/02MATINAS BIOPHARMA: Announces Topline Results from ENHANCE-IT Study of LYPDISO™ Agai..
01/02Matinas BioPharma Announces Topline Results from ENHANCE-IT Study of LYPDISO™ Against V..
27/01MATINAS BIOPHARMA HOLDINGS, INC.: Submission of Matters to a Vote of Security Holders (fo..
14/01MATINAS BIOPHARMA HOLDINGS, INC.: Regulation FD Disclosure, Financial Statements and Exhi..
06/01Matinas BioPharma to Present at the ICR Conference 2021
05/01MATINAS BIOPHARMA: Announces FDA Conditional Acceptance of LYPDISO as the Brand Name for ..
04/01MATINAS BIOPHARMA: Receives Conditional FDA OK of Lypdiso as Brand Name for MAT9001
04/01Matinas BioPharma Announces FDA Conditional Acceptance of LYPDISO™ as the Brand N..
04/01Matinas BioPharma Holdings, Inc. Announces FDA Conditional Acceptance of LYPDISO™ as th..
2020MATINAS BIOPHARMA HOLDINGS, INC.: Other Events (form 8-K)
2020MATINAS BIOPHARMA: Investor Presentat
2020MATINAS BIOPHARMA HOLDINGS, INC.: Regulation FD Disclosure, Other Events, Financial State..
2020MATINAS BIOPHARMA: Working With NIAID to Test Oral Formulations of Gilead's Remdesivir; S..
2020MATINAS BIOPHARMA: to Collaborate With NIAID to Test Remdesivir
2020Matinas BioPharma Announces Collaboration with the National Institute of Allergy and In..
2020Matinas Biopharma Holdings, Inc. Announces Collaboration with the National Institute of..
2020Matinas BioPharma Files Preliminary Proxy for Special Meeting of Stockholders
2020MATINAS BIOPHARMA HOLDINGS, INC.: Change in Directors or Principal Officers, Regulation F..
2020Matinas BioPharma Appoints Hui Liu, Ph.D., M.B.A. as Chief Technology Officer
2020Matinas BioPharma Holdings, Inc. Appoints Hui Liu as Chief Technology Officer
2020MATINAS BIOPHARMA HOLDINGS, INC.: Entry into a Material Definitive Agreement, Creation of..
2020MATINAS BIOPHARMA: Awarded up to $3.75 Million from the Cystic Fibrosis Foundation to Sup..
2020MATINAS BIOPHARMA: to Participate in Annual Piper Sandler Healthcare Conference
2020MATINAS BIOPHARMA: Receives Award of Up to $3.75 Million to Support Development of Drug C..
2020MATINAS BIOPHARMA: Awarded up to $3.75 Million from the Cystic Fibrosis Foundation to Sup..
2020Matinas BioPharma Awarded up to $3.75 Million from the Cystic Fibrosis Foundation to Su..
2020Matinas BioPharma Holdings, Inc. Awards Up to $3.75 Million from the Cystic Fibrosis Fo..
2020MATINAS BIOPHARMA: to Participate in Annual Piper Sandler Healthcare Conference
1  2  3  4Pross.
Prossimo evento su MATINAS BIOPHARMA HOLDINGS, INC.
Prossimi eventi del settore